Please login to the form below

Not currently logged in
Email:
Password:

IDO inhibitor

This page shows the latest IDO inhibitor news and features for those working in and with pharma, biotech and healthcare.

Another R&D flop for Incyte, but Jakafi keeps delivering

Another R&D flop for Incyte, but Jakafi keeps delivering

Incyte is still trying to recover from the mauling it took after its IDO inhibitor epacadostat for cancer failed earlier this year, and yesterday wrote off another programme in ... JAK1/JAK2 inhibitor Jakafi – given in combination with corticosteroids

Latest news

  • BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

    BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace. Suspends enrolment in BMS-986205 trials for NSCLC and head and neck cancer. ... Meanwhile another study of epacadostat with AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will

  • NewLink pancreatic cancer vaccine flunks phase III test NewLink pancreatic cancer vaccine flunks phase III test

    efforts on its IDO checkpoint inhibitor programme. ... The IDO inhibitor pipeline is currently led by indoximod, which is in phase II for breast cancer (in combination with taxane drugs docetaxel and paclitaxel) and prostate cancer (in combination with

  • BMS buys immunotherapy specialist Flexus in $1.2bn deal BMS buys immunotherapy specialist Flexus in $1.2bn deal

    With the addition of a potentially best-in-class IDO1 inhibitor and the broad IDO/TDO programmes, Bristol-Myers Squibb will accelerate its ability to explore numerous immunotherapeutic approaches across tumour ... the development of our potentially

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Meanwhile, despite the mixed results for checkpoint inhibitor combinations to date, there’s no let-up in the pursuit of new cocktail recipes. ... Meanwhile, Incyte’s Merck &Co partnered IDO inhibitor epacadostat bombed when paired with Keytruda in a

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    F001287, IDO1 inhibitor IDO/TDO discovery programme - immuno-oncology. Corporate acquisition. 1, 250. ... Abbreviations:. IDO, Indoleamine-2, 3-dioxygenase; TDO, Tryptophan-2, 3- dioxygenase. COPD, chronic obstructive pulmonary disease.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics